Kit Yu Lu, MD

Kit Yu Lu, MD, discussed the implications of the TROPiCS-02 and DESTINY-Breast06 trial data for sequencing ADCs in HR+/HER2– breast cancer.

Currently, sacituzumab govitecan, T-DXd, and Dato-DXd cannot be compared in HR+/HER2– breast cancer due to a lack of head-to-head trials.

Kit Yu Lu, MD, identifies patients with HR+/HER2– metastatic breast cancer who may benefit from earlier T-DXd or sacituzumab govitecan treatment.